BioSpace News Archive

Deals

Sanofi Picks Up Kiadis and Its Immuno-Oncology Assets for $359 Million

Kiadis has three compounds in the clinic: K-NK002 in Phase II for HSCT in blood cancer; K-NK003 for relapsed or refractory acute myeloid leukemia (AML); K-NK-ID101 for COVID-19.

November 2, 2020
·
3 min read
·
Mark Terry
Deals

PerkinElmer Expands Horizons with $383 Million CRISPR Tech Acquisition

Horizon Discovery Group brings new gene editing and gene modulation tools to PerkinElmer’s expanding life sciences portfolio.

November 2, 2020
·
2 min read
·
Kate Goodwin
Business

At Campaign Rally, Trump Hints He Could Fire Fauci Following the Election

During a Sunday campaign event in Florida, President Donald Trump appeared to hint to the crowd that following the Nov. 3 election, he would terminate the decades-long tenure of Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

November 2, 2020
·
3 min read
·
Alex Keown
Drug Development

Study: CureVac’s COVID-19 Vaccine CVnCoV Produces Immune Responses in Healthy Volunteers

Newly announced results of a Phase I dose-escalation study show CureVac’s COVID-19 vaccine candidate, CVnCoV, generates noticeable immune responses in healthy volunteers.

November 2, 2020
·
3 min read
·
Brandon May
Drug Development

Regeneron Hits Pause on LUMINA-1 Trial Due to Concerns with Garetosmab

Regeneron announced on Friday that it is pausing dosing of garetosmab (REGN2477), an investigational therapy, in the Phase I LUMINA-1 trial.

November 2, 2020
·
3 min read
·
Krystle Vermes
Business

Icosavax Turns VLP Tech to COVID-19 Vaccine, with $16.5 Million in New Financing

BioSpace caught up with Icosavax CEO Adam Simpson to discuss its new vaccine candidate, IVX-411.

November 2, 2020
·
5 min read
·
Gail Dutton
Perceptive Advisors Close on $1.1 Billion Credit Fund for Life Sciences Investments

The Perceptive Advisors has completed the fundraising for its third credit fund. The fund was so enticing to investors that it hit its $1.1 billion hard caps.

November 2, 2020
·
3 min read
·
Mark Terry
Business

Santhera Slashes Workforce in Half After Phase III DMD Failure

Santhera said the restructuring will allow the company to focus on the development of vamorolone, a first-in-class dissociative steroid with a novel mode of action that it gained the rights to from ReveraGen BioPharma.

November 2, 2020
·
3 min read
·
Alex Keown
Business

Evogene Financial Results and Earnings Announcement Schedule for the Third Quarter of 2020

Evogene Ltd., a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces that it will release its financial results for the third quarter of 2020 on Wednesday, November 18, 2020.

November 2, 2020
·
3 min read
Business

Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies

Collaboration Combines Fusion’s Targeted Alpha Therapies (TATs) Platform with AstraZeneca’s Antibody and Oncology Portfolio to Create Novel Cancer Therapies

November 2, 2020
·
7 min read